- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05563766
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
April 2, 2024 updated by: VA Office of Research and Development
Esophageal cancer, which has a low 5-year overall survival rate (<20%) is increasing in incidence.
Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of esophageal cancers.
Itraconazole, a widely used anti-fungal medication, effectively inhibits these pathways.
In this multi-site phase II trial, the investigators will evaluate the effect of itraconazole as a neoadjuvant therapy added to standard of care chemoradiation and surgery in the the treatment of locoregional esophageal and gastroesophageal junction cancers.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Esophageal cancer has a high incidence rate in the United States, and novel approaches to improve its treatment are being studied.
Itraconazole, an antifungal agent approved by the FDA in 1992, has been shown to inhibit the Hedgehog (Hh), AKT, and VEGFR2 signaling pathways which are upregulated in esophageal cancer and promote tumor growth.
This study will evaluate whether the use of itraconazole leads to increased rates of pathologic complete response (pathCR) by at least 15% compared to propensity-score matched control patients with esophageal or gastroesophageal junction (GEJ) cancer.
The investigators will enroll 78 patients with esophageal or GEJ cancer who will undergo standard of care staging workup with a PET/CT and endoscopic ultrasound (EUS).
If no distant metastases are found, patients will receive 2 weeks of oral itraconazole before starting standard of care neoadjuvant chemoradiation.
Upon completion of chemoradiation, patients will receive oral itraconazole for 6-8 weeks.
Adverse effects to itraconazole will be monitored and drug levels will be obtained during clinic visits.
If standard restaging PET/CT following neoadjuvant chemoradiation does not reveal new metastases, patients will undergo esophagectomy after consultation with their physician team.
Samples from normal esophageal tissue will be analyzed for presence of itraconazole and its metabolite to determine if patients were compliant in taking study drug.
Residual tumor tissue will be evaluated for status of the Hh, AKT, and VEGFR2 pathways with comparisons made to pre-treatment biopsies.
The final pathology report will indicate whether the patient has achieved pathCR.
Because Hh, AKT, and angiogenic signaling pathways can be upregulated in response to chemoradiation, the investigators believe that administering itraconazole around chemoradiation will lead to higher pathCR rates.
This in turn should be able to improve treatment outcomes in patients with esophageal and GEJ cancer.
Secondary endpoints include correlating drug levels and molecular pathway status to pathCR, determining a genomic profile that predicts treatment response, and evaluating ctDNA and exosomes as additional markers of treatment response.
Study Type
Interventional
Enrollment (Estimated)
78
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: David H Wang, MD PhD
- Phone Number: (214) 857-0737
- Email: davidh.wang@va.gov
Study Contact Backup
- Name: Jonathan Dowell, MD
- Phone Number: (214) 857-0737
- Email: Jonathan.Dowell@va.gov
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304-1290
- VA Palo Alto Health Care System, Palo Alto, CA
-
Contact:
- Albert Lin, MD
- Phone Number: 69523 650-493-5000
- Email: albert.lin6@va.gov
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Durham VA Medical Center, Durham, NC
-
Contact:
- Michael Kelley, MD
- Phone Number: 172199 919-286-0411
- Email: michael.kelley6@va.gov
-
-
Oregon
-
Portland, Oregon, United States, 97239
- VA Portland Health Care System, Portland, OR
-
Contact:
- Kenneth Bensch, MD
- Phone Number: 5594 503-220-8262
- Email: kenneth.bensch1@va.gov
-
-
Texas
-
Dallas, Texas, United States, 75216-7167
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
-
Principal Investigator:
- David H Wang, MD PhD
-
Contact:
- Amy Atwell
- Phone Number: 214-857-2234
- Email: amy.atwell@va.gov
-
Contact:
- Cedric Pereznegron
- Phone Number: (214) 857-0826
- Email: cedric.pereznegron@va.gov
-
Houston, Texas, United States, 77030
- Michael E. DeBakey VA Medical Center, Houston, TX
-
Contact:
- Yvonne Sada, MD
- Phone Number: 713-794-7454
- Email: yvonne.sada@va.gov
-
-
Washington
-
Seattle, Washington, United States, 98108
- VA Puget Sound Health Care System Seattle Division, Seattle, WA
-
Contact:
- Daniel Wu, MD
- Phone Number: 206-764-2182
- Email: daniel.wu@va.gov
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Capable of giving informed consent
- Pathologic diagnosis of esophageal cancer (ESCC or EAC) or GEJ cancer deemed resectable by a surgeon with a plan to undergo neoadjuvant chemoradiation and curative intent esophagectomy
- World Health Organization (WHO)/ECOG performance status (PS) of 0-2 at enrollment
- Adequate renal and liver function as judged by the treating physician
Exclusion Criteria:
- Inability to provide Informed Consent
- NYHA class III or IV CHF
- LFT>3X upper limit of normal
- Drug allergy to itraconazole
- Positive pregnancy test
- Those with QTc>450 ms will have QTc monitored during therapy by serial EKG to ensure QTc does not lengthen to what the treating clinician considers significant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Itraconazole
Itraconazole 300 mg po bid for two weeks prior and 6-8 weeks after completion of standard of care neoadjuvant chemoradiation
|
Itraconazole 300 mg po bid for two weeks prior and 6-8 weeks after completion of standard of care neoadjuvant chemoradiation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of pathological complete response with itraconazole
Time Frame: 20 weeks
|
Historically, the pathCR rate at time of esophagectomy is 25%.
The investigators have powered our study to detect a 15% or more improvement in pathCR rate following treatment with itraconazole.
By inhibiting pathways that mediate chemoradiation resistance, the investigators anticipate an improved pathCR rate.
|
20 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of Hedgehog, AKT, and angiogenesis pathway status before and after intervention
Time Frame: 20 weeks
|
After completion of pathologic staging of any residual tumor at esophagectomy, FFPE sections will be analyzed for expression of SHH, GLI, HER2, phospho-S6, and CD34 by IHC or ISH and compared to untreated biopsies.
|
20 weeks
|
Correlation of peripheral blood and esophageal tissue levels of itraconazole and hydroxyitraconazole with pathologic response
Time Frame: 20 weeks
|
Peripheral blood will be obtained during a standard of care clinic visit and squamous esophageal tissue collected at esophagectomy.
These levels will be correlated with pathologic response.
|
20 weeks
|
Develop a predictive genomic profile of treatment response
Time Frame: 20 weeks
|
Whole exome sequencing will be obtained on pre-treatment tumors from all enrolled patients.
VA Boston HCS will use multiple algorithms to develop a genomic profile that predicts treatment response.
|
20 weeks
|
Determine the utility of ctDNA and exosome characterization as a prognostic marker
Time Frame: 20 weeks
|
CtDNA will be obtained at 4 timepoints and exosomes will be collected at 3 timepoints during treatment.
Changes in ctDNA quantitation and exosome characteristics will be correlated with pathologic treatment response.
|
20 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: David H Wang, MD PhD, VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Zhang W, Bhagwath AS, Ramzan Z, Williams TA, Subramaniyan I, Edpuganti V, Kallem RR, Dunbar KB, Ding P, Gong K, Geurkink SA, Beg MS, Kim J, Zhang Q, Habib AA, Choi SH, Lapsiwala R, Bhagwath G, Dowell JE, Melton SD, Jie C, Putnam WC, Pham TH, Wang DH. Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway. Mol Cancer Ther. 2021 Oct;20(10):1904-1915. doi: 10.1158/1535-7163.MCT-20-0638. Epub 2021 Aug 10.
- Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, Reya T, Liu JO, Epstein EH, Stevens DA, Beachy PA. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010 Apr 13;17(4):388-99. doi: 10.1016/j.ccr.2010.02.027.
- Chen MB, Liu YY, Xing ZY, Zhang ZQ, Jiang Q, Lu PH, Cao C. Itraconazole-Induced Inhibition on Human Esophageal Cancer Cell Growth Requires AMPK Activation. Mol Cancer Ther. 2018 Jun;17(6):1229-1239. doi: 10.1158/1535-7163.MCT-17-1094. Epub 2018 Mar 28.
- Kelly RJ, Ansari AM, Miyashita T, Zahurak M, Lay F, Ahmed AK, Born LJ, Pezhouh MK, Salimian KJ, Ng C, Matsangos AE, Stricker-Krongrad AH, Mukaisho KI, Marti GP, Chung CH, Canto MI, Rudek MA, Meltzer SJ, Harmon JW. Targeting the Hedgehog Pathway Using Itraconazole to Prevent Progression of Barrett's Esophagus to Invasive Esophageal Adenocarcinoma. Ann Surg. 2021 Jun 1;273(6):e206-e213. doi: 10.1097/SLA.0000000000003455.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 1, 2024
Primary Completion (Estimated)
April 30, 2029
Study Completion (Estimated)
June 15, 2029
Study Registration Dates
First Submitted
September 27, 2022
First Submitted That Met QC Criteria
September 28, 2022
First Posted (Actual)
October 3, 2022
Study Record Updates
Last Update Posted (Actual)
April 3, 2024
Last Update Submitted That Met QC Criteria
April 2, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Neoplasms, Squamous Cell
- Carcinoma, Squamous Cell
- Disease Progression
- Carcinoma
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Pathologic Complete Response
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Itraconazole
Other Study ID Numbers
- ONCB-016-21F
- I01CX002349 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Adenocarcinoma
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal Adenocarcinoma | Stage IIB Esophageal Adenocarcinoma | Stage IB Esophageal Adenocarcinoma | Stage IIA Esophageal AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingGastroesophageal Junction Adenocarcinoma | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage II Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IIA Esophageal... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)TerminatedAdenocarcinoma of the Gastroesophageal Junction | Stage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal Adenocarcinoma | Stage IIB Esophageal AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedGastroesophageal Junction Adenocarcinoma | Stage IB Esophageal Adenocarcinoma AJCC v7 | Stage II Esophageal Adenocarcinoma AJCC v7 | Stage IIA Esophageal Adenocarcinoma AJCC v7 | Stage IIB Esophageal Adenocarcinoma AJCC v7 | Stage IIIA Esophageal Adenocarcinoma AJCC v7 | Stage IIIB Esophageal...United States
-
Roswell Park Cancer InstituteUnited States Department of DefenseRecruitingClinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastroesophageal Junction... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions
-
Memorial Sloan Kettering Cancer CenterRecruitingMetastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastric Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Cancer | Unresectable Esophageal Cancer | Metastatic Esophageal Carcinoma | Metastatic Gastric... and other conditionsUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingClinical Stage IV Gastric Cancer AJCC v8 | Metastatic Gastric Adenocarcinoma | Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8 | Clinical... and other conditionsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditionsUnited States, Puerto Rico
-
National Cancer Institute (NCI)Active, not recruitingClinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Malignant Neoplasm in the Brain and other conditionsUnited States
Clinical Trials on Itraconazole
-
University of Maryland, BaltimoreCompleted
-
University of Alabama at BirminghamWashington University School of Medicine; University of California, DavisCompletedInvasive Fungal InfectionsUnited States, Panama
-
Johns Hopkins UniversityMemorial Sloan Kettering Cancer CenterCompleted
-
Sara BotrosCompleted
-
Pulmatrix Inc.Completed
-
University of Kansas Medical CenterUniversity of Texas, Southwestern Medical Center at DallasRecruitingBarrett Oesophagitis With DysplasiaUnited States
-
Halcygen Pharmaceuticals LimitedCompletedOnychomycosisUnited States
-
H. Lundbeck A/SCompletedCytochrome P450 InteractionUnited Kingdom, United States
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompletedOnychomycosisUnited States, South Africa, Canada, Dominican Republic, Ecuador, Honduras, Panama
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedNon-small Cell Lung Cancer MetastaticUnited States